WO1999047925A3 - Methods and compositions for diagnosis of rheumatoid arthritis - Google Patents

Methods and compositions for diagnosis of rheumatoid arthritis Download PDF

Info

Publication number
WO1999047925A3
WO1999047925A3 PCT/GB1999/000763 GB9900763W WO9947925A3 WO 1999047925 A3 WO1999047925 A3 WO 1999047925A3 GB 9900763 W GB9900763 W GB 9900763W WO 9947925 A3 WO9947925 A3 WO 9947925A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
compositions
rpis
methods
rheumatoid arthritis
Prior art date
Application number
PCT/GB1999/000763
Other languages
French (fr)
Other versions
WO1999047925A2 (en
Inventor
Rajesh Bhikhu Parekh
Thakorbhai Parshotambhai Patel
Robert Reid Townsend
Original Assignee
Oxford Glycosciences Uk Ltd
Rajesh Bhikhu Parekh
Thakorbhai Parshotambhai Patel
Robert Reid Townsend
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd, Rajesh Bhikhu Parekh, Thakorbhai Parshotambhai Patel, Robert Reid Townsend filed Critical Oxford Glycosciences Uk Ltd
Priority to AU29429/99A priority Critical patent/AU756588B2/en
Priority to EP99910490A priority patent/EP1062509A2/en
Priority to CA002323238A priority patent/CA2323238A1/en
Priority to JP2000537069A priority patent/JP2002507723A/en
Publication of WO1999047925A2 publication Critical patent/WO1999047925A2/en
Publication of WO1999047925A3 publication Critical patent/WO1999047925A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods and compositions for screening, diagnosis and prognosis of RA, for monitoring the effectiveness of RA treatment, and for drug development. RA-Diagnostic Features (RADFs), detectable by two-dimensional electrophoresis of serum or plasma are described. The invention further provides RA-Diagnostic Protein Isoforms (RPIs) detectable in synovial fluid, serum or plasma, preparations comprising isolated RPIs, antibodies immunospecific for RPIs, and kits comprising the aforesaid.
PCT/GB1999/000763 1998-03-13 1999-03-15 Methods and compositions for diagnosis of rheumatoid arthritis WO1999047925A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU29429/99A AU756588B2 (en) 1998-03-13 1999-03-15 Methods and compositions for diagnosis of rheumatoid arthritis
EP99910490A EP1062509A2 (en) 1998-03-13 1999-03-15 Methods and compositions for diagnosis of rheumatoid arthritis
CA002323238A CA2323238A1 (en) 1998-03-13 1999-03-15 Methods and compositions for diagnosis of rheumatoid arthritis
JP2000537069A JP2002507723A (en) 1998-03-13 1999-03-15 Methods and compositions for the diagnosis of rheumatoid arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805477.8A GB9805477D0 (en) 1998-03-13 1998-03-13 Methods and compositions for diagnosis of rheumatoid arthritis
GB9805477.8 1998-03-13

Publications (2)

Publication Number Publication Date
WO1999047925A2 WO1999047925A2 (en) 1999-09-23
WO1999047925A3 true WO1999047925A3 (en) 1999-11-25

Family

ID=10828567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000763 WO1999047925A2 (en) 1998-03-13 1999-03-15 Methods and compositions for diagnosis of rheumatoid arthritis

Country Status (8)

Country Link
EP (1) EP1062509A2 (en)
JP (1) JP2002507723A (en)
CN (1) CN1300367A (en)
AU (1) AU756588B2 (en)
CA (1) CA2323238A1 (en)
GB (1) GB9805477D0 (en)
WO (1) WO1999047925A2 (en)
ZA (1) ZA992079B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858210B1 (en) * 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
IL153189A0 (en) 2000-06-19 2003-06-24 Correlogic Systems Inc Heuristic method of classification
KR101054732B1 (en) 2000-07-18 2011-08-05 더 유나이티드 스테이츠 오브 아메리카 애즈 리프리젠티드 바이 더 세크레터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 How to Identify Biological Conditions Based on Hidden Patterns of Biological Data
WO2002054079A2 (en) * 2000-10-24 2002-07-11 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of cardiac response
EP1368647A2 (en) * 2000-12-29 2003-12-10 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of vascular response
AU2002216273A1 (en) * 2000-12-29 2002-07-16 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
DE10127572A1 (en) * 2001-05-30 2002-12-05 Pathoarray Gmbh Tools for the diagnosis, molecular definition and therapy development of chronic inflammatory joint diseases
US20030100016A1 (en) * 2001-11-23 2003-05-29 George Jackowski Complement C3 precursor biopolymer markers predictive of Alzheimers disease
NL1019540C2 (en) * 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Method for detecting autoantibodies from patients suffering from rheumatoid arthritis, peptide and assay kit.
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2004011905A2 (en) 2002-07-29 2004-02-05 Correlogic Systems, Inc. Quality assurance/quality control for electrospray ionization processes
CN1871362A (en) * 2003-09-05 2006-11-29 皇家妇女医院 Diagnostic marker for ovarian cancer
JP4774534B2 (en) 2003-12-11 2011-09-14 アングーク ファーマシューティカル カンパニー，リミティド A diagnostic method for biological status through the use of a centralized adaptive model and remotely manipulated sample processing
SG182976A1 (en) 2007-06-29 2012-08-30 Ahngook Pharmaceutical Co Ltd Predictive markers for ovarian cancer
ES2568702B1 (en) * 2014-10-01 2017-02-13 Servizo Galego De Saude (Sergas) METHOD FOR THE DIAGNOSIS OF ARTROSIS
CN106950365B (en) * 2017-02-15 2018-11-27 中国医学科学院北京协和医院 A kind of RA diagnosis marker of ACPA feminine gender and its application
CN108732253A (en) * 2017-04-14 2018-11-02 杭州量康科技有限公司 Peptide fragment composition and assay method for serous proteinquatative measurement

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175310A1 (en) * 1984-09-14 1986-03-26 ASAHI MEDICAL Co., Ltd. A substantially pure rheumatoid arthritis specific protein and an antibody against the same
EP0378732A1 (en) * 1989-01-20 1990-07-25 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Serum proteins related to autoimmune disease
WO1995016919A2 (en) * 1993-12-17 1995-06-22 Matritech, Inc. Methods and compositions for the detection of colon cancers
WO1998009170A2 (en) * 1996-08-30 1998-03-05 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US5837686A (en) * 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175310A1 (en) * 1984-09-14 1986-03-26 ASAHI MEDICAL Co., Ltd. A substantially pure rheumatoid arthritis specific protein and an antibody against the same
EP0378732A1 (en) * 1989-01-20 1990-07-25 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Serum proteins related to autoimmune disease
US5837686A (en) * 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
WO1995016919A2 (en) * 1993-12-17 1995-06-22 Matritech, Inc. Methods and compositions for the detection of colon cancers
WO1998009170A2 (en) * 1996-08-30 1998-03-05 Matritech, Inc. Methods and compositions for the detection of cervical cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EKI, TOSHIHIKO ET AL: "Fifteen open reading frames in a 30.8 kb region of the right arm of chromosome VI from Saccharomyces cerevisiae", YEAST (1996), 12(2), 177-90, XP002116970 *
HANSEN, JORGEN ET AL: "Two divergent MET10 genes, one from Saccharomyces cerevisiae and one from Saccharomyces carlsbergensis, encode the.alpha. subunit of sulfite reductase and specify potential binding sites for FAD and NADPH", J. BACTERIOL. (1994), 176(19), 6050-8, XP002116973 *
HOSSEINI-MAZINANI, S. M. ET AL: "Cloning and sequencing of sulfite reductase.alpha.-subunit gene from Saccharomyces cerevisiae", DNA RES. (1995), 2(1), 15-19, XP002116972 *
MURAKAMI, YASUFUMI ET AL: "Analysis of the nucleotide sequence of chromosome VI from Saccharomyces cerevisiae", NAT. GENET. (1995), 10(3), 261-8, XP002116971 *

Also Published As

Publication number Publication date
AU756588B2 (en) 2003-01-16
EP1062509A2 (en) 2000-12-27
CN1300367A (en) 2001-06-20
CA2323238A1 (en) 1999-09-23
JP2002507723A (en) 2002-03-12
WO1999047925A2 (en) 1999-09-23
GB9805477D0 (en) 1998-05-13
AU2942999A (en) 1999-10-11
ZA992079B (en) 2000-10-10

Similar Documents

Publication Publication Date Title
WO1999047925A3 (en) Methods and compositions for diagnosis of rheumatoid arthritis
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
AU4073297A (en) Methods and compositions for the detection of cervical cancer
WO2000005265A3 (en) Anti-crr2 antibodies and methods of use therefor
WO1999037788A3 (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
EP1379693A4 (en) Bio-barcodes based on oligonucleotide-modified particles
DE69434942D1 (en) MULTIPURPOSE REAGENT SYSTEM FOR THE FAST LYSING OF FULL BLOOD SAMPLES
EP1687283A4 (en) Method and composition useful for determining fk 506
EP0921395A3 (en) Assays for measurement of protein fragments in biological media
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
AU5169998A (en) Methods for detecting cell apoptosis
DE69822307D1 (en) HUMAN ADAMTS-1 PROTEIN, GENE WHICH CODES THIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR THE IMMUNOLOGICAL DETERMINATION OF HUMAN ADAMTS-1 PROTEINS
MX9604183A (en) A screening method for identifying ligands for target proteins.
AU6659698A (en) Compositions, methods, kits and apparatus for determining the presence or absence of target molecules
WO2001013117A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
EP0753743A3 (en) Vitamin D assay
AU5143099A (en) Protein fragment complementation assays for the detection of biological or drug interactions
GB2384206A (en) Automated system for two-dimensional electrophoresis
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
WO2001063294A3 (en) Diagnosis of bipolar affective disorder (bad) and unipolar depression
WO2001063293A3 (en) Diagnosis and treatment of schizophrenia
AU3589101A (en) Dpi-6, a putative therapeutic target and biomarker in neuropsychiatric and neurological disorders
WO2001069261A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99806001.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2323238

Country of ref document: CA

Ref document number: 2323238

Country of ref document: CA

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 29429/99

Country of ref document: AU

Ref document number: 09660632

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 506979

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09622267

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999910490

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999910490

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 29429/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999910490

Country of ref document: EP